Literature DB >> 11189685

Coordination and management of a large multicenter screening trial: the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial.

B O'Brien1, L Nichaman, J E Browne, D L Levin, P C Prorok, J K Gohagan.   

Abstract

The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial is a large and complex multi-institutional, multifaceted organization with a 20-year horizon. The implementation of the trial began with the creation of an organizational structure that supports strong leadership, cooperation, and effective communication among the trial collaborators including an operational framework for the development, review, and pretest of instruments, data collection, and management procedures; the setting of high-quality standards for training of trial staff; and the development of a comprehensive assessment plan for evaluation of all trial activities. This paper describes the process and methods used in the coordination and management of the PLCO trial. These include the role of the steering committee and its subcommittees and working groups, the establishment of regular and ad hoc communications among collaborators, the training of screening center coordinators and examiners, the PLCO manual of operations and procedures, and the development and implementation of a comprehensive quality assurance plan.

Entities:  

Mesh:

Year:  2000        PMID: 11189685     DOI: 10.1016/s0197-2456(00)00099-4

Source DB:  PubMed          Journal:  Control Clin Trials        ISSN: 0197-2456


  8 in total

1.  Flexible sigmoidoscopy in the randomized prostate, lung, colorectal, and ovarian (PLCO) cancer screening trial: added yield from a second screening examination.

Authors:  Joel L Weissfeld; Robert E Schoen; Paul F Pinsky; Robert S Bresalier; V Paul Doria-Rose; Adeyinka O Laiyemo; Timothy Church; Lance A Yokochi; Susan Yurgalevitch; Joshua Rathmell; Gerald L Andriole; Saundra Buys; E David Crawford; Mona Fouad; Claudine Isaacs; Lois Lamerato; Douglas Reding; Philip C Prorok; Christine D Berg
Journal:  J Natl Cancer Inst       Date:  2012-01-31       Impact factor: 13.506

2.  Ovarian cancer biomarker performance in prostate, lung, colorectal, and ovarian cancer screening trial specimens.

Authors:  Daniel W Cramer; Robert C Bast; Christine D Berg; Eleftherios P Diamandis; Andrew K Godwin; Patricia Hartge; Anna E Lokshin; Karen H Lu; Martin W McIntosh; Gil Mor; Christos Patriotis; Paul F Pinsky; Mark D Thornquist; Nathalie Scholler; Steven J Skates; Patrick M Sluss; Sudhir Srivastava; David C Ward; Zhen Zhang; Claire S Zhu; Nicole Urban
Journal:  Cancer Prev Res (Phila)       Date:  2011-03

3.  Sexually transmissible infections and prostate cancer risk.

Authors:  Wen-Yi Huang; Richard Hayes; Ruth Pfeiffer; Raphael P Viscidi; Francis K Lee; Yun F Wang; Douglas Reding; Denise Whitby; John R Papp; Charles S Rabkin
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2008-09       Impact factor: 4.254

4.  Identifying and collecting pertinent medical records for centralized abstraction in a multi-center randomized clinical trial: the model used by the American College of Radiology arm of the National Lung Screening Trial.

Authors:  Ilana F Gareen; JoRean D Sicks; Amanda Adams Jain; Denise Moline; Nancy Coffman-Kadish
Journal:  Contemp Clin Trials       Date:  2012-09-11       Impact factor: 2.226

5.  Cumulative incidence of false-positive results in repeated, multimodal cancer screening.

Authors:  Jennifer Miller Croswell; Barnett S Kramer; Aimee R Kreimer; Phil C Prorok; Jian-Lun Xu; Stuart G Baker; Richard Fagerstrom; Thomas L Riley; Jonathan D Clapp; Christine D Berg; John K Gohagan; Gerald L Andriole; David Chia; Timothy R Church; E David Crawford; Mona N Fouad; Edward P Gelmann; Lois Lamerato; Douglas J Reding; Robert E Schoen
Journal:  Ann Fam Med       Date:  2009 May-Jun       Impact factor: 5.166

6.  Differential blood-based diagnosis between benign prostatic hyperplasia and prostate cancer: miRNA as source for biomarkers independent of PSA level, Gleason score, or TNM status.

Authors:  Petra Leidinger; Martin Hart; Christina Backes; Stefanie Rheinheimer; Bastian Keck; Bernd Wullich; Andreas Keller; Eckart Meese
Journal:  Tumour Biol       Date:  2016-01-29

Review 7.  Overdiagnosis and overtreatment of early detected prostate cancer.

Authors:  C H Bangma; S Roemeling; F H Schröder
Journal:  World J Urol       Date:  2007-02-14       Impact factor: 4.226

8.  A mathematical model of case-ascertainment bias: Applied to case-control studies nested within a randomized screening trial.

Authors:  Rick J Jansen; Bruce H Alexander; Richard B Hayes; Anthony B Miller; Sholom Wacholder; Timothy R Church
Journal:  PLoS One       Date:  2018-03-19       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.